OSI-461

Overview

OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

OSI-461 is a second-generation molecule belonging to a new class of drugs termed selective apoptotic anti-neoplastic drugs (SAANDs).

Investigated for use/treatment in crohn's disease, inflammatory bowel disease, kidney cancer, leukemia (lymphoid), and prostate cancer.

No associated conditions information available.

Title	Posted	Study ID	Phase	Status	Sponsor
A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL)	2003/11/25	NCT00073489	Phase 2	Completed	Astellas Pharma Inc
CP-461 in the Treatment of Patients With Advanced Melanoma	2003/05/13	NCT00060710	Phase 2	Terminated	Astellas Pharma Inc
CP-461 for the Treatment of Crohn's Disease	2002/07/24	NCT00042055	Phase 2	Completed	Astellas Pharma Inc
Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia	2002/05/09	NCT00036257	Phase 1	Completed	Astellas Pharma Inc
Study of CP-461 in Patients With Advanced Renal Cell Cancer	2002/05/08	NCT00036036	Phase 2	Completed	Astellas Pharma Inc
Study Using CP-461 to Treat Advanced Prostate Cancer	2002/05/08	NCT00036075	Phase 2	Completed	Astellas Pharma Inc

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

No news found